The Clatterbridge Cancer Centre, UK, selects RayStation with RayOcular
STOCKHOLM, March 26, 2021 /PRNewswire/ -- The Clatterbridge Cancer Centre NHS Foundation Trust, located in Liverpool, UK, has placed an order for the RayStation® treatment planning system with RayOcular*- a new module for ocular proton therapy treatment planning.
The order is a milestone for RaySearch since it marks the first standalone sale of RayOcular, where the module is not included as part of a broader agreement.
The Clatterbridge Cancer Centre has treated ocular melanoma using proton therapy since 1989 and has been a pioneer in developing this specialized technique. One example is the center's leading role in the community-driven development of EYEPLAN, a non-image-based ocular proton therapy planning system.
The RayOcular module was initially released in RayStation 10A (June 2020). RayStation is the first commercial treatment planning system to support the use of CT and MRI images in the traditional clip-based ocular proton planning workflow. In addition, RayStation with RayOcular supports eye modeling based on ophthalmological data and tumor modeling based on fundus photos.
Chris Lee, Lead Consultant Clinical Scientist in Specialised Services at The Clatterbridge Cancer Centre, says: "We are very much looking forward to working with RaySearch and are excited with the prospect of collaborating to develop our eye proton planning process along with RayOcular for the benefit of patients. As part of the commissioning plan we will be investigating the use of 3D imaging (CT/MRI) used as part of RayOcular planning and will look to adopt this in the treatment pathway. RayOcular will open up new treatment planning oportunities which we will hope to exploit for improved patient plans."
Johan Löf, founder and CEO, RaySearch, says: "The Clatterbridge Cancer Centre is one of the world's leading ocular proton therapy centers. The center's relatively early adoption of RayOcular sends a strong signal that we are on the right track with ocular proton planning in RayStation. We look forward to advancing this area in partnership."
The order was received in December 2020 and the order value was SEK 5.6 million, excluding service agreement.
About the Clatterbridge Cancer Centre
* Subject to regulatory clearance in some markets.
More information about RaySearch is available at www.raysearchlabs.com
For further information, please contact:
Peter Thysell, CFO, RaySearch Laboratories AB (publ)
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
SOURCE RaySearch Laboratories
Company Codes: Bloomberg:RAYB@SS, ISIN:SE0000135485, RICS:RAYB.ST, Stockholm:RAYB